64
Participants
Start Date
May 31, 2015
Primary Completion Date
January 31, 2017
Study Completion Date
January 31, 2017
Exenatide
"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
Insulin
"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
Post operative intensive care unit of the cardiac surgery department, Besançon
Collaborators (1)
AstraZeneca
INDUSTRY
Eli Lilly and Company
INDUSTRY
Centre Hospitalier Universitaire de Besancon
OTHER